Manthi 😎

THIS IS HUGE! A cancer vaccine developed by Yale University and DFCI shows MAJOR promise. Results of an early-phase trial reveal ALL patients with ADVANCED stage kidney cancer had successful anti-cancer immune responses AND have remained CANCER-FREE approximately THREE years after treatment. 🧪🧵⬇️

IMPORTANT THINGS TO NOTE !! • KEEP IN MIND THESE ARE RESULTS THAT HAVE HELD UP APPROXIMATELY THREE YEARS showing that benefits demonstrated years ago have held up over time. That is ASTOUNDING. • Researchers say the results of a Phase I trial of an therapeutic cancer vaccine aimed at preventing kidney cancer show promise. • This new study found that ALL patients with ADVANCED stage kidney cancer had successful anti-cancer immune responses AND have remained CANCER-FREE approximately THREE years after treatment. • The study, demonstrates the potential of personalized vaccines to change the course of certain cancer types, but larger, longer trials are needed to confirm this approach. • Cancer vaccines developed with different molecular recipes are still in their early stages, before strong conclusions can be made. • While the findings are encouraging, the vaccine is still in early testing and will likely take years before it becomes widely available.

How personalized peptide cancer vaccines work Scientists identify neoantigens, abnormal proteins produced by cancer cells. They take a sample of the patient's mutated cancer cells. The neoantigens are used to create a vaccine tailored to the patient's tumor. The vaccine is administered, prompting the immune system to target the cancer cells with those proteins. The immune system's T-cells attack and destroy the tumor cells, shrinking the cancer.

ABSTRACT Personalized cancer vaccines (PCVs) can generate circulating immune responses against predicted neoantigens. However, whether such responses can target cancer driver mutations, lead to immune recognition of a patient's tumour and result in clinical activity are largely unknown. These questions are of particular interest for patients who have tumours with a low mutational burden. Here we conducted a phase l trial (ClinicalTrials.gov identifier NCTO2950766) to test a neoantigen-targeting PCV in patients with high-risk, fully resected clear cell renal cell carcinoma (RCC; stage Ill or IV) with or without ipilimumab administered adjacent to the vaccine. At a median follow-up of 40.2 months after surgery, none of the 9 participants enrolled in the study had a recurrence of RCC. No dose-limiting toxicities were observed. All patients generated T-cell immune responses against the PCV antigens, including to RCC driver mutations in VHL, PBRM1, BAP1, KDM5C and PIK. Following vaccination, there was a durable expansion of peripheral T-cell clones. Moreover, T-cell reactivity against autologous tumours was detected in seven out of nine patients. Our results demonstrate that neoantigen-targeting PCVs in high-risk RCC are highly immunogenic, capable of targeting key driver mutations and can induce antitumour immunity. These observations, in conjunction with the absence of recurrence in all nine vaccinated patients, highlights the promise of PCVs as effective adjuvant therapy in RCC.

This study involved a large and collaborative team across multiple institutions, with key leadership from co-senior authors Toni Choueiri, Derin Keskin, Patrick Ott, and Catherine Wu from DFCI. Research reported in this release was supported by the National Institutes of Health under award numbers 1R37CA279822-01 and P30CA016359. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The research was also funded by the Gateway for Cancer Research, U.S. Department of Defense, Louis Goodman and Alfred Gilman Yale Scholar Fund, Yale Cancer Center, Dana-Farber/ Harvard Cancer Center, Harvard Medical School, Trust Family Foundation, Michael Brigham, Pan Mass Challenge, Hinda L. and Arthur Marcus Foundation, The Loker Pinard Fund for Kidney Cancer Research at Dana-Farber Cancer Institute, and Conquer Cancer Foundation/Sontag Foundation.

The study has been published in Nature. YES, it is PEER-REVIEWED.
• www.nature.com/articles/s41...

IMPORTANT THINGS TO NOTE ‼️

Bonjour lepen est mort j’espère que vous célébrez bien

Sachez que je continuerais d'utiliser les pires googles trad possible car ça me fume.

⚖️ Le procès pour soupçons d'emplois fictifs d'assistants parlementaires européens du Rassemblement national et de Marine Le Pen s'est achevé mercredi, le tribunal rendra son jugement le 31 mars.

Jsuis épuisée mais j’arrive pas à dormir 😪

Bonsoir,

C'est non.

Passez une bonne soirée et à demain.

Ptdrr je pensais que j'étais encore sur Twitter et que c'était un article sérieux

Etre sur Bluesky avant l’arrivée des twittos

Ça me fume ça a vraiment une vibe de Twitter à l’ancienne

Bluesky pourrait mettre en place place les cercles 🔥🔥🔥🔥🔥

Faut enlever le «bsky.social» par contre hein c'est vraiment pas beau.

Bon et bien ça ne sera pas pour ce matin la bonne nouvelle. Purée dites lui de lâcher le morceau

Y'a AUCUNE pub sur la TL c'est tellement rafraîchissant purée

JUREZ ????

Macron démission.